CareLit · DOI-Nachweis · Pneumologie
Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced o…
DOI 10.1055/s-0034-1367776
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ von Pawel, G Scagliotti, S Novello, R Ramlau, A Favaretto, F Barlesi, W Akerley, S Orlov, A Santoro, F Shepherd, D Spigel, V Hirsh, L Sequist, D Shuster, H Zahir, Q Wang, B Schwartz, R von Roemeling, AB Sandler
ZeitschriftPneumologie
Ausgabe02/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: MARQUEE, a Phase 3 study investigating the role of tivantinib (T), a c-MET inhibitor, in prev. treated non-squamous NSCLC, collected EGFR/KRAS genotype on > 90% of random. pats, MET expr. was determined for 42%. In the ITT population, add. of tivantinib to erlotinib (E) signif. improved PFS and ORR but did not show benefit in OS. Add. efficacy analyses in the pre-defined molecular subgroups are presented…
Zitieren
Zitierempfehlung
J von Pawel, G Scagliotti, S Novello, R Ramlau, A Favaretto, F Barlesi, W Akerley, S Orlov, A Santoro, F Shepherd, D Spigel, V Hirsh, L Sequist, D Shuster, H Zahir, Q Wang, B Schwartz, R von Roemeling, AB Sandler (2014) Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCL…. Pneumologie (02). https://doi.org/10.1055/s-0034-1367776
Mit CareLit weiterarbeiten